Mylan Ends Calif. Drug Price Inflation Claims For $57M

Law360, New York (February 27, 2012, 7:21 PM EST) -- Mylan Inc. will pay $57 million to resolve all claims by the state of California and a relator in multidistrict litigation accusing the drugmaker of reporting inflated average wholesale prices of drugs to the California Medicaid program, according to court documents filed Monday.

Mylan and its units Mylan Pharmaceuticals Inc. and Mylan Institutional Inc., which had previously paid $65 million to settle similar claims by Texas in January 2011, will now pay $22 million to the U.S., $26 million to California and $7 million to California...
To view the full article, register now.